Back to today’s briefing

Story perspectives

Pharmacogenomics Trial Expands to 1,450 Participants for Safer Prescriptions

2/12/2025

48 4

Summary

Story summary

The PROGRESS pharmacogenomics trial in England is set to grow significantly, having already adjusted prescriptions for 28% of its initial 250 participants. Originally launched in June 2023, the trial will now welcome 1,450 additional participants until December 2025, utilizing a groundbreaking tool to seamlessly incorporate pharmacogenomic insights into prescribing systems, ensuring safer medication practices in primary care.

1 of 1

Story summary

The PROGRESS pharmacogenomics trial in England is set to grow significantly, having already adjusted prescriptions for 28% of its initial 250 participants. Originally launched in June 2023, the trial will now welcome 1,450 additional participants until December 2025, utilizing a groundbreaking tool to seamlessly incorporate pharmacogenomic insights into prescribing systems, ensuring safer medication practices in primary care.